http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 10:49:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15/26658320.html si-local-file:///var/storage/secattach/20260617/26658320.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15/26658320.html Wed, 17 Jun 2026 10:49:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15/26658320.html si-local-file:///var/storage/secattach/20260617/26658320.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15/26658320.html Wed, 17 Jun 2026 10:49:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Whiting+Nancy/26649055.html si-local-file:///var/storage/secattach/20260615/26649055.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Whiting+Nancy/26649055.html Mon, 15 Jun 2026 19:41:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Whiting+Nancy/26649055.html si-local-file:///var/storage/secattach/20260615/26649055.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Whiting+Nancy/26649055.html Mon, 15 Jun 2026 19:41:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lim+Jonathan+E/26649045.html si-local-file:///var/storage/secattach/20260615/26649045.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lim+Jonathan+E/26649045.html Mon, 15 Jun 2026 19:36:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lim+Jonathan+E/26649045.html si-local-file:///var/storage/secattach/20260615/26649045.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lim+Jonathan+E/26649045.html Mon, 15 Jun 2026 19:36:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Christensen+James/26649038.html si-local-file:///var/storage/secattach/20260615/26649038.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Christensen+James/26649038.html Mon, 15 Jun 2026 19:32:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Christensen+James/26649038.html si-local-file:///var/storage/secattach/20260615/26649038.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Christensen+James/26649038.html Mon, 15 Jun 2026 19:32:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lew+Jennifer/26649030.html si-local-file:///var/storage/secattach/20260615/26649030.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lew+Jennifer/26649030.html Mon, 15 Jun 2026 19:29:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lew+Jennifer/26649030.html si-local-file:///var/storage/secattach/20260615/26649030.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+15++Filed+by%3A+Lew+Jennifer/26649030.html Mon, 15 Jun 2026 19:29:00 -0400 BOLD O.15817313 http://www.streetinsider.com/Earnings/Audentes+Therapeutics+%28BOLD%29+Tops+Q1+EPS+by+20c/26458177.html <p>Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80).</p><p>For earnings history and earnings-related data on Audentes Therapeutics (BOLD) <a href="http://www.streetinsider.com/ec_earnings.php?q=BOLD">click here</a>.</p> http://www.streetinsider.com/Earnings/Audentes+Therapeutics+%28BOLD%29+Tops+Q1+EPS+by+20c/26458177.html Fri, 08 May 2026 08:15:12 -0400 BOLD http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Boundless+Bio%2C+Inc.+++++++For%3A+Mar+31/26457549.html si-local-file:///var/storage/secattach/20260508/26457549.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Boundless+Bio%2C+Inc.+++++++For%3A+Mar+31/26457549.html Fri, 08 May 2026 07:11:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Boundless+Bio%2C+Inc.+++++++For%3A+Mar+31/26457549.html si-local-file:///var/storage/secattach/20260508/26457549.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Boundless+Bio%2C+Inc.+++++++For%3A+Mar+31/26457549.html Fri, 08 May 2026 07:11:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+May+08/26457500.html si-local-file:///var/storage/secattach/20260508/26457500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+May+08/26457500.html Fri, 08 May 2026 07:05:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+May+08/26457500.html si-local-file:///var/storage/secattach/20260508/26457500.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Boundless+Bio%2C+Inc.+++++++For%3A+May+08/26457500.html Fri, 08 May 2026 07:05:00 -0400 BOLD O.15817313 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Press+Releases/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344 http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html <p align="center"><em>Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940</em></p> <p align="center"><em>$93 million in cash provides runway through expected clinical proof-of-concept </em><em>readout for KOMODO-1</em></p> <p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=WgZG2Lhm5iGY8hLPbN7QuV5SFay_avGB9C1eF6qGmRe4Cw2KqVEauxWHq9dpyND0IiKph6QaqjbL8fZPu9-rWw==" rel="nofollow" target="_blank">Boundless Bio</a> (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.</p> <p align="justify">“We are encouraged by the progress of the KOMODO-1 trial,&quot; said Zachary Hornby, President and Chief Executive http://www.streetinsider.com/Globe+Newswire/Boundless+Bio+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26457398.html Fri, 08 May 2026 07:00:00 -0400 A.06822034 A.35552990 BOLD O.00074346 O.15817313 O.20026344